HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific antibody) combined with chemotherapy as a first-line treatment for locally advanced unresectable or metastatic triple-negative breast cancer (TNBC) at the 2025 European Society for Medical Oncology Immuno-Oncology Congress (ESMO IO) in London, UK. Based on positive

A new type of blood test can accurately identify different types of breast cancer – meaning patients can be matched to the correct treatment without the need for a biopsy. Researchers have shown that the blood test, called Breast Circulating Methylation Assay (BCMA), can track a cancer’s type over time and pick up if it has changed – meaning that treatment can be quickly adapted. There are many different types of breast cancer – for example, oestrogen receptor positive, human epidermal growth fa

- Data reflect new insights and precision oncology advancements in portfolio and pipeline - - Cohort results from Phase 2 ILUSTRO study evaluating a zolbetuximab triplet combination regimen in first-line advanced gastric and gastroesophageal junction (GEJ) cancer featured in late-breaking oral presentation - TOKYO, Dec. 10, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced it will present data on potential treatments for pancreati

TAIPEI and SAN DIEGO, Dec. 10, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company developing first-in-class therapies for difficult-to-treat cancers, today announced a clinical supply agreement with BeOne Medicines, a global oncology company. This agreement will supply a global, multi-center Phase 1b/2a clinical trial to evaluate Senhwa's lead compound Pidnarulex (CX-5461) in combination with BeOne's tislelizumab, a PD-1 inhibitor, in patients

New AI models integrating imaging, clinical, and molecular data from the TAILORx tissue biorepository show stronger prognostic performance than current methods to predict recurrence risk in early-stage breast cancer and guide long-term treatment decisions PHILADELPHIA and IRVING, Texas, Dec. 10, 2025 /PRNewswire/ -- Today at the San Antonio Breast Cancer Symposium (SABCS), researchers presented the initial findings from a major multi-year collaboration between the ECOG-ACRIN Cancer Research Grou

CRANFORD, N.J., Dec. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the closing of its previously announced registered direct offering with a single healthcare-focused investor, priced at-the-market under Nasdaq rules, for the purchase and sale of 1,284,404 shares of its common stock at a purchase price of $1.09 per share. In addit

CAMBRIDGE, Mass., Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Ron Squarer to its Board of Directors. "We welcome Ron to our Board of Directors, where his personal dedication to advancing oncology therapeutics, demonstrated success in evolving research and development organizations to fully integrated busine

Key Highlights: First-in-human milestone: The inaugural patient has been dosed with PRV131. Precise, localized delivery: Built on Privo's PRV Platform technology, PRV131 delivers high concentrations of cisplatin directly to tumors, while minimizing systemic exposure. BOSTON, Mass., Dec. 10, 2025 /PRNewswire/ -- Privo Technologies, Inc., today announced that the first patient has been dosed in its first-in-human clinical trial evaluating PRV131, a nanoengineered intratumoral cisplatin injectab

BURLINGTON, Mass., Dec. 10, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its Board of Directors has approved a share repurchase program under which the company may repurchase up to $250 million of its outstanding common stock. The Repurchase Program is intended to enhance shareholder value and capitalize on undervaluation. Repurchases may be made from time to time through open market repurchases, privately negotiated transactions, or by other methods compliant with Rules

HORSHAM, Pa., Dec. 10, 2025 /PRNewswire/ -- Biocoat today announced the formation of Surmodics Services & Technologies, a newly named division that will carry forward the portion of Biocoat's business remaining after merging with Surmodics and divesting certain Biocoat assets in connection with the transaction. Surmodics Services & Technologies represents the legacy Biocoat business operations that were not divested. This division will now operate as part of the Surmodics organization under its